Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia.

Clin Epigenetics · 2019 · PMC6647096 · PMID 31331399

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

As previously reported, KRAS and NRAS mutations were mutually exclusive, and there was a strong trend for RAS mutations (N or K) to be associated with resistance to guadecitabine (CR cases were seen in 0/22 (0%) patients with RAS mutations compared to 15/100 (15%) patients without RAS mutations, p = 0.07).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.